Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Vaccination of chickens, against Marek’s Disease (MD), with a modified serotype 1 Marek’s disease virus (MDV1), containing a reticuloendotheliosis virus LTR, and the parental herpesvirus of turkey (HVT) strain FC126

Proposed period of release:
01/04/2021 to 31/01/2023

Name of the Institute(s) or Company(ies)
Boehringer Ingelheim Animal health France (BIAH), 29 avenue Tony Garnier, 69007 Lyon, France;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
The vaccine contains two active ingredients but only one GMO construct based on herpesviruses belonging to the Mardivirus genus: RN1250 and the already known HVT FC126.
RN1250 is a serotype 1 Marek’s disease virus (MDV; Gallid alphaherpesvirus 2) chimera based on the MDV CVI988 parental vaccine virus that contains two copies of reticuloendotheliosis virus (REV) long terminal repeats (LTR) from MDV RM1 strain inserted in its genome.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Serotype 1 Marek’s disease virus (MDV)MardivirusGallid alphaherpesvirus 2-CVI988 (Rispens)-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known